Conjunctival Vascularity Changes Usnig OCTA After Trabeculectomy

NCT ID: NCT04493073

Last Updated: 2020-07-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-01

Study Completion Date

2022-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Reduce the trauma and the time taken for patient rehabilitation.
* The prevailing trend is to perform a mitomycin- C (MMC)-augmented trabeculectomy and trabeculectomy with ologen implants in a trial to decrease bleb failure as a common post- trabeculectomy complication.
* Is to develop a measurement protocol by OCT-A imaging and characterization of the bleb vascularity changes in glaucoma patients before and after surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main purpose of this project is to compare bleb vascularity changes using optical coherence tomography (OCT-A) between mitomycin- C (MMC)-augmented trabeculectomy and develop trabeculectomy with ologen implants to determine whether bleb vascularity measurements during preoperative and early postoperative periode could act as surrogate parameters to predict surgical outcomes.

Glaucoma often existent in the elderly population. Measuremets of bleb vascularity beginning to become an essential part of the glaucoma specialist's clinical and operative took. As investigators continue to collect data both clinically and in the laboratory, these various imaging modalities will shepherd surgeons into a more precise and predicable era of glaucoma surgeries.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

OCTA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Trabectulectomy with mitomycin

Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India) 10 mg vial 2 mg/ml concentration

Group Type ACTIVE_COMPARATOR

Trabectulectomy

Intervention Type PROCEDURE

decrease IOP

Mitomycin

Intervention Type DRUG

Decrease bleb failure

Mitomycin-C Kyowa®

Intervention Type DEVICE

Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India)

Trabectulectomy with Ologen implants

Ologen Collagen Implant (Aeon Astron Europe, Netherlands) - three-dimensional collagen- GAG implant \>90% lyophilized porcine atelocollagen and \<10% lyophilized porcine GAG 12 mm in diameter with 1 mm of thickness and 6 mm in diameter with 2 mm of thickness

Group Type ACTIVE_COMPARATOR

Trabectulectomy

Intervention Type PROCEDURE

decrease IOP

Ologen Collagen Implant

Intervention Type DEVICE

Ologen Collagen Implant (Aeon Astron Europe, Netherlands)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Trabectulectomy

decrease IOP

Intervention Type PROCEDURE

Mitomycin

Decrease bleb failure

Intervention Type DRUG

Ologen Collagen Implant

Ologen Collagen Implant (Aeon Astron Europe, Netherlands)

Intervention Type DEVICE

Mitomycin-C Kyowa®

Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ologen implants

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients older than 18 years of age with primary or secondary open-angle glaucoma.
* Primary OAG (POAG) diagnosed on the basis of IOP measurements more than 21 mmHg, open angle on gonioscopy (Grade 3 or 4 on Schaffer grading system for angle width), glaucomatous visual field defects consistent with glaucomatous optic disc changes.
* PNAG was diagnosed by the presence of narrow or occludable angle on gonioscopy (Grade 2, or 1 on Schaffer grading system for angle width in at least 180° of the total circumference of the angle in primary position without indentation), glaucomatous optic disc changes, visual field defects and IOP more than 21 mmHg

Exclusion Criteria

* pregnant or lactating female.
* previous intraocular surgery
* one-eyed patients.
* previous ocular trauma.
* uveitis-induced glaucoma, neovascular glaucoma, aphakic/pseudophakic glaucoma
* systemic connective tissue disease and missing more than 3 follow-up visits.
* Trabeculectomy augmented by either MMC or Ologen implant was indicated to study subjects if they had uncontrolled IOP under maximum antiglaucoma medications (3 antiglaucoma drugs) or due to poor socioeconomic status.
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Asmaa Ahmed Ali Youssif

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Asmaa Ahmed Ali Youssif

doctor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohamed Saad

Role: STUDY_DIRECTOR

Assiut University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Asmaa Ali, PhD

Role: CONTACT

01002475442

Khaled Abd El azzem, PhD

Role: CONTACT

01114001717

References

Explore related publications, articles, or registry entries linked to this study.

He M, Wang W, Zhang X, Huang W. Ologen implant versus mitomycin C for trabeculectomy: a systematic review and meta-analysis. PLoS One. 2014 Jan 20;9(1):e85782. doi: 10.1371/journal.pone.0085782. eCollection 2014.

Reference Type BACKGROUND
PMID: 24465704 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OCTA after Trabeculectomy

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety of XEN63 Gel Implant
NCT06844240 ENROLLING_BY_INVITATION
Primary Tube Versus Trabeculectomy Study
NCT00666237 COMPLETED PHASE4